Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data
Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy
Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms intriple-class refractory multiple myeloma
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
Best Practices in the Curation and Use of Real-world Data in the Regulatory Pathway
Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study
Use of Real-World Evidence in a Virtual Bridging Analysis for a Human Epidermal Growth Factor Receptor 2–Targeted Antibody–Drug Conjugate in Gastric Cancer
Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011−2021
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
